Recent evidence suggests that passenger leukocytes migrate after organ transplantation and produce persistent chimerism, which is essential for sustained survival of the allograft. Here, we describe how this hematolymphopoietic chimerism provides an important framework for interpretation of post-transplant phenomena and for initiation of therapeutically oriented transplantation research.
Introduction
A link between bone marrow and organ transplantation was provided when microchimerism was detected with sensitive immunocytochemical and polymerase chain reaction techniques in the tissues or blood of 30 human kidney or liver recipients studied from 2.5 to 30 years postoperatively [1, 2] . The donor cells were multilineage, but paradoxically many appeared to be dendritic cells (DCs), a potent antigen-presenting cell [3] . Individual samples from patients often do not contain the donor leukocytes, which wax and wane [4] . However, disseminated donor cells including DCs, or alternatively donor DNA, are consistently demonstrable if rodents bearing long-term grafts are thoroughly studied [5] [6] [7] .
Along with peripheral migration of the donor cells from a successfully transplanted graft, there is an influx of host leukocytes that do not cause graft damage [2] . Thus, both the allograft and recipient become genetic composites (Fig. 1a) . A mirror image condition exists after bone marrow transplantation [8] (Fig. 1b) , proved by demonstrating a trace residual population of host leukocytes in essentially all stable human bone marrow recipients who previously were thought to have complete donor-cell chimerism [9] .
Previous enigmas
These discoveries have provided an important framework for a better understanding of allograft 'acceptance', for analysis of management problems, and for therapeutically oriented transplantation research [10-°]. In the new context of this two-way paradigm, the donor leukocytes in organ recipients constitute the small member of antagonistic but reciprocally attenuated or abrogated host-versus-graft (HVG) and graft-versus-host (GVH) arms, each of which can induce specific nonreactivity (tolerance) in the other [1,2,8] (Fig. 2) . Deletion of the host arm by the cytoablation before bone marrow but not before organ transplantation alters the balance in this mutual interaction and is thus responsible for the disparities in the two different kinds of transplantation (Table O. The dynamic 'nullification' effect of the two arms makes it obvious why kidney recipients can sometimes stop immunosuppression without losing their allografts [10°°] . It also explains the poor prognostic value of human leukocyte antigen matching for organ transplantation, the rarity of GVH disease after the engraftment of immunologically active organs such as the intestine and liver, and 
Two-way paradigm with which transplantation is seen as a bidirectional and mutually cancelling immune reaction that is (a) predominantly host-versus-graft (HVG) with whole organ grafts, and (b) predominantly graft-versus-host (GVH) with bone marrow grafts. IL--_==--=c:. =-_=~-==d".:.~=-=--=--=_=. c=U the characteristic cycle of immunologic crisis and resolution, first observed in kidney recipients [11] , that was most practically monitored by serial changes in organ allograft function (Fig. 2) .
The two-way paradigm defines success and failure after transplantation in a different way than before. Success implies that chimerism has been introduced which mayor may not be immunosuppression-dependent. Failure connotes the therapeutically uncontrollable ascendency of HVG or GVH. Pathologic evidence of both processes is (Q 1997 Current Opinion in Nephrology and Hypertension frequently found in failed liver or intestinal transplant cases, but the ultimate result is predominantly rejection or GVH disease. In kidney recipients who are exposed to a small load of passenger leukocytes, findings in the recipient and allograft are essentially always interpreted in the context of rejection.
The counter-argument
In the previous conception of organ allograft acceptance, which excluded a role for lymphoid cell microchimerism, it was axiomatic that antigens of the parenchymal (or 
Contem poran eo us host-versus-graft (HVG) and graft-versus-host (GVH) reactions in the two-way paradigm of transplantation immunology. After the initial interaction, the evolution of nonreactivity of each leukocyte population to the other is seen as a predominantly low-grade stimulatory state that may wax and wane, rather than a deletional one. 
Post-transplant Iymphoproliferative disorders
The two-way paradigl.l also has shed light on the pathogenesis of post-transplant lymphoproliferative disorders (PTLDs) Table 1 . Differences between conventional bone marrow and organ transplantation
Bone Marrow 
Therapeutic implications
Understanding the concept of the donor-recipient leukocyte dialogue inherent in the two-way paradigm helps in predicting what can (and cannot) be accomplished with various tolerance-inducing strategies, all of ,vhich arc attempts to influence this immunologic interaction.
Adjunct leukocyte infusion
Historic efforts to improyc organ transplantation results with donor-specific blood transfusion [31] or donor bone marrow [32, 33] were based on sound therapeutic principles involving the unrecognized augmentation of chimerism. In an extension of these pioneer trials, our premise was that the spontaneous microchimerism of organ transplantation could be greatly augmented bv the coChimerism after organ transplantation Starzl et al. 295 administration of unmodified donor bone marrow cells without a significant risk of GVH disease, providing the two immllnocyte populations were initially competent and that immunosuppression was delivered to both equally. It also was predicted that the timing, se,'eritv, and frequency of acute rejection would be approximately the same as in non-marrow augmented control patients [1, 34, 35] .
These expectations have been fulfilled in 200 human organ recipients trcated at the University of Pittsburgh [35,36··,37] , including 86 who were given kidneys. The presence of donor D~A in myeloid and erythroid colonies generated from recipients' peripheral blood mononuclear cells as measured in standard [36. 0 ] or innovative clonal hematopoietic progenitor cell assays [38·] has provided unequivocal eyidence of augmented stem-cell chimerism. There were no examples of significant GVH disease.
The hypotheses of therapeutic efficacy being rested are that the threat of delayed (acute or chronic) rejection can be reduced and that the frequency of ultimate drug independence can be increased by the higher persistent level of chimerism. An efficacy evaluation is expected to take S to 10 vears [10·· ,3Sl, which is roughly the same time frame for tolerance induction learned from clinical experience with major histocompatibility complex-incompatible liver and bone marrow transplantation [10 0 .,34].
Hematolymphopoietic growth factors
The usc of hematopoietic growth factors is another potential chimerism-enhancing strategy that is well established in bone marrow, but not in organ, transplantation. Granulocyte-macrophage colony-stimulating factor (Gl\1-CSF), and granulocyte colony-stimulating factor arc two cytokines that act at an early point in the hematopoietic cascade. [45, 50] . Because numbers both of donor and of host hematopoietic cells of multiple lineages are increased by administration of GM-CSF, granulocyte colony-stimulat-ing factor, and FIt3 ligand, these cytokines (particularly Flt3 ligand) may provide a pharmacologic means of enhancing organ transplant chimerism.
Predictable hazards
As with donor leukocyte infusion, such cytokine therapy is expected to be safe only if both cell populations are subject to the same conditions of immune suppression (i.e. growth factor treatmcnt is started perioperatively). In contrast, alterations of only one of the interacting arms must be approached with caution, as exemplified by the historical experience with GVH disease after cytoablation and bone marrow transplantation. 'Vhen the converse tactic of leukocyte or T-cell specific depletion of intestinal allografts was attempted as GVH disease prophylaxis in the 1980s, virtually every bowel recipient who survived the perioperative period developed lethal EBV-associated B-ceillymphomas [51] .
Unbalance also can be caused by delayed proVisIOn of donor leukocytes (e.g. repeat infusion of adjunct donor bone marrow to an organ recipient). To the extent that the first exposure (whether to infused leukocytes or to passenger leukocytes in a transplanted organ) induces tolerance, the result of the second stage delivery can resemble the effect of a parent to defenseless offspring Fl hybrid experiment. T nvestigarors signing on for multicenter trials of serial bone marrow augmentation should be made aware of the consequent increased risk of GVH disease.
Xenotransplantation
Guidelines elucidated by the rwo-wa·y paradigm will dictate strategies of xenotransplantation. The feasibility of producing stable xenogeneic chimerism has been demonstrated in pigs given unaltered primate bone marrow intravenously a few hours after birth, without any immunosuppression [52°] . Because the primary source of complement is the liver, not the hematolymphopoietic system, it is unlikely that humoral rejection caused by the interspecies complement activation will he ahrogated, no matter what the duration of chimerism [52-] . However, by inducing chimerism in pigs who already have human complement regulatory proteins in their organs at birth, the barrier of complement activation and cellular tolerance may be jointly approach cd by clinical strategies that are discussed elsewhere [52°].
Conclusion
The assumption that stem-cell driven hematolymphopoietic chimerism was irrelevant to successful whole organ transplantation as currently practiced has led to inadequate explanations of organ allograft acceptance and clouded the meaning of successful hone marrow transplantation. This has therefore precluded the development of a central principle of transplantation. Incorporation of the chimerism factor into a two-way paradigm has allowed previous enigmas of organ as well as bone marrow engraftment to be explained and should allow key advances in basic immunology to he more meaningfully exploited in transplantation, including development of xenotransplantation.
